Therapeutic Response

IDH2 p.R172K status confers therapeutic sensitivity to Vorasidenib in patients with Astrocytoma.

Statements

Source and description
Voranigo (vorasidenib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.
Voranigo (vorasidenib) [product monograph]. HC. Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.